ADAR1 Antibodies

Santa Cruz Biotechnology provides a broad selection of ADAR1 monoclonal antibodies for research focused on understanding RNA editing mechanisms. ADAR1 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). ADAR1, or adenosine deaminase acting on RNA 1, plays a vital role in editing RNA molecules, significantly impacting gene expression and cellular stress responses. RNA editing by ADAR1 is particularly significant during viral infections and autoimmune conditions, where it helps modulate immune responses by editing viral RNA and preventing harmful pathway activation. Research has shown that ADAR1 dysfunction can lead to various pathological conditions, making it an important target for therapeutic development. Understanding ADAR1's molecular mechanisms and cellular functions continues to reveal new insights into RNA biology and disease processes. Investigating ADAR1's role in different biological pathways helps advance our knowledge of RNA editing mechanisms and their impact on human health. ADAR1 research has opened new avenues for developing targeted therapies for various diseases, including autoimmune disorders and viral infections. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of RNA editing mechanisms and their therapeutic applications.